Skip to main content
Ir a la página de inicio de la Comisión Europea (se abrirá en una nueva ventana)
español es
CORDIS - Resultados de investigaciones de la UE
CORDIS

X-chromosome role in SEx-dependent Lymphoma Evolution and Clonal Trajectories

Objetivo

Despite recent advances, we still lack a coherent framework explaining how genetic lesions, aberrant cell fate decisions and host factors intersect to drive immunological neoplasms (lymphoma). We have uncovered an entirely new dimension: gender bias as a fundamental driver of lymphoma evolution. Our data show that a newly discovered type of lymphoma called BN2-DLBCL, defined by SPEN and NOTCH2 truncations, is specifically highly aggressive in women and rooted in the biology of aged/autoimmune B cells (AiBCs); cells classically linked to autoimmunity. This suggests a central role for female gender effects where immune dysfunction, chronic inflammation, and failed X-chromosome inactivation (XCI) converge. We hypothesize that SPEN loss destabilizes XCI, unleashing bi-allelic expression of X-encoded TLR7/IRAK1 and hyperactive inflammatory signaling; NOTCH2 mutations reroute these signals into AiBC fate, creating lymphoma precursors that expand clonally, exhaust T cells, and reshape immune microenvironments. The result is a uniquely female-biased malignant trajectory, overturning conventional lymphoma paradigms. With X-SeLECT (X-chromosome role in SEx-dependent Lymphoma Evolution and Clonal Trajectories) we will systematically dissect this biology. Using single-cell multi-omics, spatial proteogenomics, real-time dynamics (3-photon microscopy), and lineage tracing, we will reconstruct the stepwise clonal evolution of AiBCs into BN2-DLBCL and define the gender-specific immune circuits that sustain them. Finally, we will exploit these insights to uncover sex-specific vulnerabilities, testing how TLR/IRAK blockade, statins, and immune checkpoint synergy can dismantle these malignant networks. This project will deliver a paradigm shift: establishing AiBCs as the first bona fide lymphoma-initiating and repopulating cells, demonstrating that gender and X-linked immunity are central to cancer biology, and charting the way toward precision, sex-informed therapies in lymphoma.

Ámbito científico (EuroSciVoc)

Este proyecto aún no se ha clasificado con EuroSciVoc.
Sugiera los ámbitos científicos que considere más relevantes y ayúdenos a mejorar nuestro servicio de clasificación.

Palabras clave

Programa(s)

Tema(s)

Régimen de financiación

HORIZON-ERC - HORIZON ERC Grants

Ver todos los proyectos financiados en el marco de este régimen de financiación

Convocatoria de propuestas

(se abrirá en una nueva ventana) ERC-2025-ADG

Ver todos los proyectos financiados en el marco de esta convocatoria

Institución de acogida

FUNDACIO INSTITUT DE RECERCA CONTRA LA LEUCEMIA JOSEP CARRERAS
Aportación neta de la UEn
€ 3 499 123,75
Dirección
CARRETERA DE CAN RUTI CAMI DE LES ESCOLES S/N
08916 Badalona
España
Región
Este Cataluña Barcelona
Tipo de actividad
Research Organisations
Enlaces
Coste total
Sin datos

Beneficiarios (1)